Elucid Secures $55 Million in Latest Series D Funding Round

Elucid secured $55 million in its latest Series D, adding another data point to the Healthcare & Life Sciences funding market.

Elucid Raises $55 million in Funding

Elucid Raises $55 Million in Oversubscribed Series D Financing. [.] Elucid is a Boston-based medical technology company dedicated to bringing precision patient care, as currently practiced in oncology, to cardiology.

Investors Behind the Funding

The round was backed by Elevage Medical Technologies | Elucid. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Elucid operates in Healthcare & Life Sciences. Elucid's financing adds to recent private-market activity.

Strategic Use of Funds

combat heart disease

Looking Ahead

Elucid Raises $55 Million in Oversubscribed Series D Financing

Source reference: original announcement/article.